BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 25581263)

  • 1. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
    Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
    Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
    Ma DW; Arendt BM; Hillyer LM; Fung SK; McGilvray I; Guindi M; Allard JP
    Nutr Diabetes; 2016 Jul; 6(7):e220. PubMed ID: 27428872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
    Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
    Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
    Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study.
    Allard JP; Aghdassi E; Mohammed S; Raman M; Avand G; Arendt BM; Jalali P; Kandasamy T; Prayitno N; Sherman M; Guindi M; Ma DW; Heathcote JE
    J Hepatol; 2008 Feb; 48(2):300-7. PubMed ID: 18086506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis.
    Ding WJ; Wang Y; Fan JG
    Arch Iran Med; 2014 Aug; 17(8):563-8. PubMed ID: 25065280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease.
    Pettinelli P; Arendt BM; Teterina A; McGilvray I; Comelli EM; Fung SK; Fischer SE; Allard JP
    PLoS One; 2018; 13(10):e0205747. PubMed ID: 30379862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
    Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
    Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease.
    Arendt BM; Teterina A; Pettinelli P; Comelli EM; Ma DWL; Fung SK; McGilvray ID; Fischer SE; Allard JP
    Nutrition; 2019 Jun; 62():100-107. PubMed ID: 30870804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition.
    Arendt BM; Mohammed SS; Ma DW; Aghdassi E; Salit IE; Wong DK; Guindi M; Sherman M; Heathcote EJ; Allard JP
    Curr HIV Res; 2011 Mar; 9(2):128-35. PubMed ID: 21434863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lipidomic analysis of nonalcoholic fatty liver disease.
    Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
    Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight.
    Okada LSDRR; Oliveira CP; Stefano JT; Nogueira MA; Silva IDCGD; Cordeiro FB; Alves VAF; Torrinhas RS; Carrilho FJ; Puri P; Waitzberg DL
    Clin Nutr; 2018 Oct; 37(5):1474-1484. PubMed ID: 29249532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.
    López-Vicario C; González-Périz A; Rius B; Morán-Salvador E; García-Alonso V; Lozano JJ; Bataller R; Cofán M; Kang JX; Arroyo V; Clària J; Titos E
    Gut; 2014 Feb; 63(2):344-55. PubMed ID: 23492103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes.
    Petit JM; Guiu B; Duvillard L; Jooste V; Brindisi MC; Athias A; Bouillet B; Habchi M; Cottet V; Gambert P; Hillon P; Cercueil JP; Verges B
    Clin Nutr; 2012 Aug; 31(4):520-5. PubMed ID: 22209679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
    Kawaguchi T; Itou M; Taniguchi E; Sata M
    Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
    Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
    PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
    Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
    Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.